Talazoparib nanoparticles for overcoming multidrug resistance in triple‐negative breast cancer
Author:
Affiliation:
1. Department of Medical Biology, Faculty of MedicineSakarya UniversitySakarya Turkey
2. Department of Medical Biology, Faculty of MedicineUludag University Bursa Turkey
Publisher
Wiley
Subject
Cell Biology,Clinical Biochemistry,Physiology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcp.29552
Reference60 articles.
1. Development, Maintenance, and Reversal of Multiple Drug Resistance: At the Crossroads of TFPI1, ABC Transporters, and HIF1
2. A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair
3. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)
4. Increased Expression of P-Glycoprotein and Doxorubicin Chemoresistance of Metastatic Breast Cancer Is Regulated by miR-298
5. deBono J. S.(2013). First‐in‐human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors. In ASCO (p. Abstract No: 2580).https://doi.org/10.1200/jco.2013.31.15_suppl.2580
Cited by 21 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The use of nanomaterials as drug delivery systems and anticancer agents in the treatment of triple-negative breast cancer: an updated review (year 2005 to date);Discover Nano;2024-09-03
2. Development of an RP-HPLC method to evaluate the basic characteristics of talazoparib-loaded PLGA nanoparticles;Journal of Chemical Metrology;2024-06-28
3. Cost-effectiveness of talazoparib for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US;Scientific Reports;2024-06-17
4. Recent Developments in Combination Immunotherapy with Other Therapies and Nanoparticle-Based Therapy for Triple-Negative Breast Cancer (TNBC);Cancers;2024-05-25
5. Development of biotin decorated Olaparib loaded cationic lipopolymeric hybrid nanoparticle and evaluation of its anticancer effect and pharmacokinetics for triple negative breast cancer;Journal of Drug Delivery Science and Technology;2024-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3